| Heading: |
Cancer: Medical Treatments |
| Question ID: |
1805300 |
| UIN: |
HL7769 |
| House: |
Lords |
| Date tabled: |
2025-05-21 |
| Asking Member ID: |
4948 |
| Asking Member display name: |
Lord Markham
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Lord Markham
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what steps they are taking to measure the effectiveness of and potential to rapidly adopt cancer therapies that require non-genomic biomarker testing. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-09 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Medicines and Healthcare products Regulatory Agency (MHRA) has a key role in assessing the safety and efficacy of any medicine, and newly licensed medicines are appraised by the National Institute for Health and Care Excellence (NICE).The NICE routine... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |